Salih, Teresita T.
HRN: 21-53-95 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/06/2022
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
08/06/2022
08/12/2022
IV
100mg
Q24
CAP HR
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Guideline Not Available
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes